Amount of suitable clients: CDEC talked over the uncertainty in the number of patients with moderately significant to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical authorities consulted by CADTH indicated that some sufferers that are labeled as obtaining delicate or reasonable disorder may have a extreme bleeding